BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification FDA Launches Framework to Accelerate Individualized Therapies for Ultra Rare Diseases 2026 OncoDaily RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban Ars Technica FDA Category 2 Update: The 5 Peptides Still Facing Heavy Review As excitement builds around peptides potentially moving off the FDA Category 2 list, it's important to understand one key reality: Not